Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir for CMV Prevention in Lung Transplant
NCT00227370Phase 3Completed
- Sponsor
- Duke University
- Start
- Jul 2003
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cytomegalovirus infection (CMV) comparing Extended Valganciclovir with Placebo (2 arms). Primary endpoints: Incidence of CMV End Organ Disease at 300 days and Incidence of CMV Syndrome at 300 days. Started Jul 2003; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00227370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00227370.